Pharmaceutical Research Insight

offers a comprehensive view of the global neuromodulation devices market. The report analyses recent trends in this market and anticipates the progression in the market over the next decade with global, regional and submarket forecasts.

At a breakfast fund-raiser last year at the Liaison Capitol Hill hotel, former lobbyist Paul Equale pulled up a chair next to Sen. Richard Durbin. As they chatted, the Illinois Democrat told him about a recent breakthrough in his efforts to push through a bill to cap debit-card fees.

Telaprevir is currently priced at USD 49,200 for 12 weeks of therapy, while boceprevir is priced at USD 1,100 per week, for a total treatment cost of anywhere between USD 26,400 to USD 48,400 depending on individual patient response to therapy.